https://alert.psychnews.org/2022/08/fda-approves-novel-rapid-acting-oral.html
Auvelity, an extended-release tablet that combines dextromethorphan and bupropion
Dextromethorphan, commonly used as a cough suppressant, inhibits the NMDA receptor, which is the same receptor targeted by the rapid-acting antidepressant esketamine. The antidepressant bupropion inhibits the metabolic enzyme CYP2D6, which prolongs the time that dextromethorphan remains active.
